A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Clinical trial NCT06328673 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06328673
- Sponsor
- D2M Biotherapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-09
- Primary completion
- 2026-03-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.